Understanding the mechanisms of action of new drugs is a key success factor for efficient drug discovery. It’s necessary for:
Thus, understanding the mechanisms of action is needed at all steps in the drug development pipeline, from discovery to clinical trials and regulatory approval.
Inovotion’s in vivo assays provide ample access to tumors, allowing a deep analysis of its mechanisms of action including transcriptomics, metabolomics, proteomics, immune cell infiltration, histological analysis, target validation, and others.
During the webinar, Xavier Rousset will discuss:
Speaker: Xavier Rousset, PhD, Research Scientist, Inovotion
Xavier is the head of Inovotion's R&D department. He joined Inovotion at its creation in 2015 and oversees the development of new tests and readouts. He leads client projects and initiates technological improvements to meet specific customer requests.
Xavier has extended Inovotion's tests to cover Immuno-Oncology. He has developed dozens of new cancer models and set up standardized data sets for their associated reference molecules.
Xavier earned his PhD in physiology and physiopathology at the University Pierre et Marie Curie of Paris, working on lipid metabolism. He then held several postdoctoral positions in the USA at the NIH National Heart, Lung and Blood Institute in Bethesda and in France (Université Grenoble Alpes) moving to cancer research.